Ocular Therapeutix (OCUL) Research & Development (2013 - 2026)

Ocular Therapeutix has reported Research & Development for 14 years, with the latest figure at $54.1 million in Q2 2026.

• Research & Development for Q2 2026 came in at $54.1 million, up 5.98% year-over-year; the trailing twelve-month figure through Jun 2026 was $223.5 million (up 29.96% YoY), and the FY2025 annual result was $197.1 million, up 54.42% from the prior year.
• Research & Development fell to $54.1 million in Q2 2026, from $66.2 million in the prior quarter.
• Over five years, Research & Development peaked at $66.2 million in Q1 2026 and troughed at $13.1 million in Q1 2022.
• A 5-year average of $31.1 million and a median of $24.8 million in 2024 frame the typical range for Research & Development.
• The widest annual swing landed in 2022, when Research & Development decreased 5.48%; it then jumped 153.1% in 2024.
• A 5-year view of Research & Development shows it stood at $13.5 million in 2022, then rose by 19.58% to $16.2 million in 2023, then jumped by 153.1% to $41.0 million in 2024, then grew by 23.94% to $50.8 million in 2025, then rose by 6.57% to $54.1 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $54.1 million in Q2 2026, $66.2 million in Q1 2026, and $50.8 million in Q4 2025.